Celltrion signs $72.8 million deal for migraine drug Ajovy

Celltrion has secured a $72.8 million deal with TEVA Pharmaceuticals for CDMO services.

2024-10-22

Celltrion to form subsidiary for contract development and manufacturing

The pharmaceutical firm said it will set up a fully owned subsidiary for CDMO to capitalize on its expertise in antibody development and production.

2024-10-18

Celltrion establishes Vietnamese office, eyes sale approvals by end of year

Celltrion established a Vietnamese entity in a move to accelerate its market penetration into the Southeast Asian country.

2024-09-30

Celltrion's SteQeyma approved to treat inflammatory disease in Britain

Celltrion’s biosimilar drug SteQeyma, a copy of Janssen's Stelara, has been approved in Britain for multiple inflammatory diseases.

2024-09-04

Celltrion, Celltrion Pharm cancel merger due to shareholder pushback

Celltrion and Celltrion Pharm announced Friday that they will not proceed with their previously planned merger, citing objections from Celltrion’s shareholders.

2024-08-16

Celltrion posts record-high revenue on overseas drug sales

Celltrion achieved record revenue of 874.7 billion won driven by overseas biosimilar sales.

2024-08-07

Celltrion's Remsima SC grabs 40% market share in Germany

Celltrion is quickly expanding its presence in Germany, with its rheumatoid arthritis copycat drug Remsima SC grabbing nearly 40 percent of the local market, more than a 10-fold surge in just four years.

2024-05-07